pomalidomide has been researched along with Central Nervous System Neoplasm in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Atherton, PJ; DeAngelis, LM; Grommes, C; Jaeckle, KA; Johnston, PB; Koenig, PA; O'Neill, B; Omuro, AMP; Pederson, LD; Pulido, J; Reeder, CB; Schiff, D; Tun, HW; Witzig, TE | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Babusis, D; Copland, JA; Edenfield, B; Huang, P; Katz, J; Li, Z; Moghaddam, MF; Personett, D; Qiu, Y; Shirely, MA; Tang, Y; Tun, HW | 1 |
| Dalto, S; Montefusco, V; Mussetti, A | 1 |
| Gertz, MA | 1 |
1 review(s) available for pomalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
1 trial(s) available for pomalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retinal Neoplasms; Thalidomide; Treatment Outcome | 2018 |
4 other study(ies) available for pomalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Successful treatment with pomalidomide and intrathecal injections for central nervous system plasmacytoma in a patient under haemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Dexamethasone; Female; Humans; Injections, Spinal; Plasmacytoma; Renal Dialysis; Thalidomide; Treatment Outcome | 2020 |
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.
Topics: Angiogenesis Inhibitors; Animals; Cells, Cultured; Central Nervous System Neoplasms; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lymphoma; Male; Mice; Mice, Nude; Rats; Thalidomide; Tumor Microenvironment; U937 Cells | 2013 |
Effective treatment of pomalidomide in central nervous system myelomatosis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Pomalidomide and myeloma meningitis.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Humans; Male; Multiple Myeloma; Thalidomide | 2013 |